CA
ATYR

Continuum Advisory’s aTyr Pharma ATYR Stock Holding History

Continuum Advisory’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-210
Closed -$634 – 1639
2025
Q1 		$634 Hold
210
– – ﹤0.01% 1563
2024
Q4 		$760 Hold
210
– – ﹤0.01% 1667
2024
Q3 		$670 Buy
+210
New +$382 ﹤0.01% 1720

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Continuum Advisory's ATYR Position: Q2 2025 in Review

Continuum Advisory sold out of aTyr Pharma (ATYR) in Q2 2025, closing a stake of 210 shares — an estimated $634 sold.

Continuum Advisory first reported a position in ATYR in Q3 2024 and held it in 3 quarters. The position peaked at $760 in Q4 2024. 110 funds tracked by Wall St. Rank hold ATYR as of Q2 2025.

  • Continuum Advisory reported no remaining aTyr Pharma position as of Q2 2025 after selling out during the quarter.
  • Continuum Advisory sold 210 aTyr Pharma shares in Q2 2025, an estimated $634.
  • Continuum Advisory first reported a position in aTyr Pharma in Q3 2024 and held it in 3 quarters.
  • Continuum Advisory's aTyr Pharma position peaked at $760 in Q4 2024.
  • 110 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2025.

Based on Continuum Advisory's 13F filing for Q2 2025, filed 13 Aug 2025.